What is the difference between mcg and mg in B12 dosing
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

The state of hepatic GH resistance in anorexia nervosa is further corroborated by the lack of increase in IGF-I following administration of supraphysiological doses of exogenous GH in women with anorexia nervosa (61), and only refeeding appears to able to restore IGF-I levels (56, 59, 62)
The absence of specific guidance reflects the lack of robust clinical trial data in this population
It's about strategic support based on how tirzepatide actually works in your bodythe reduced food intake, the slower gastric emptying, the metabolic changes that affect nutrient absorption
Bone 190 , 117326 (2025)